Thus, targeting Wnt signaling pathway inhibitors, such as sclerostin, DKK1, WIF1, and SFRP, to regulate the expression of key molecules in the Wnt pathway represents a promising and safe therapeutic strategy for osteoporosis. This evidence concerns the gene WIF1 and osteoporosis.